Key terms

About CRDF

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CRDF news

Apr 08 4:23pm ET Cardiff Oncology Reveals Latest Cancer Research at AACR by TipRanks Apr 08 4:12pm ET Cardiff presents data underscoring ‘significant potential’ of onvansertib by TipRanks Mar 06 6:14am ET Cardiff Oncology price target raised to $14 from $12 at H.C. Wainwright by TipRanks Mar 01 8:50am ET Cardiff Oncology price target raised to $7 from $5 at Piper Sandler by TipRanks Mar 01 7:48am ET Cardiff Oncology (CRDF) Gets a Buy from Piper Sandler by TipRanks Feb 29 8:05pm ET TD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF) by TipRanks Feb 29 4:36pm ET Cardiff Oncology reports Q4 EPS (93c), consensus (28c) by TipRanks Feb 29 4:35pm ET Cardiff Oncology provides update on discontinued ONSEMBLE trial data by TipRanks Feb 29 4:23pm ET Cardiff Oncology Reports Progress in Colorectal Cancer Trials by TipRanks Feb 29 4:17pm ET Cardiff Oncology doses first patient in CRDF-004 trial by TipRanks Jan 17 10:31am ET Cardiff Oncology: Findings of Phase 1b study published in peer-reviewed journal by TipRanks

No recent press releases are available for CRDF

CRDF Financials

1-year income & revenue

Key terms

CRDF Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CRDF Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

The logo of Swiss bank UBS is seen at the company's headquarters in Zurich, Switzerland February 10, 2015. REUTERS/Arnd Wiegmann/File Photo
Arnd Wiegmann/Reuters
Switzerland says UBS may need more cash. The bank is fuming
Jamie Dimon, Chairman and Chief Executive officer (CEO) of JPMorgan Chase & Co. (JPM) speaks to the Economic Club of New York in Manhattan in New York City, U.S., April 23, 2024. REUTERS/Mike Segar
Mike Segar/Reuters
Jamie Dimon fears for the future of the free world and US debt
A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings